Earth's first planetary defense

Earth is hit by asteroids all the time, but to avoid severe damages in the future NASA's Double Asteroid Redirection Test ...
Dealbreaker on MSN

Aktis has first biotech IPO of 2026, raising $318M to expand the reach of radiopharmaceuticals

Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted ...

U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO

No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week. Read ...